Skip to main content
. 2020 Feb 7;37(3):1233–1247. doi: 10.1007/s12325-020-01243-y

Fig. 5.

Fig. 5

Results of scenario analyses. ICER incremental cost-effectiveness ratio, VN voretigene neparvovec